Quarterly ResultMay 14, 2026, 07:32 AM
Biofrontera Q1 Revenue +17% to $10.1M; Gross Margin 80%
AI Summary
Biofrontera Inc. reported strong financial results for Q1 2026, with revenues increasing 17% year-over-year to $10.1 million and gross margins expanding significantly to 80%. The company also saw an improved operating loss and Adjusted EBITDA, with cash consumption near zero. Operationally, Biofrontera achieved several milestones, including FDA acceptance of its sNDA for Ameluz® PDT for sBCC with a September 2026 PDUFA date, positive Phase 3 results for AK, and positive Phase 2b data for acne.
Key Highlights
- Q1 2026 revenue increased 17% to $10.1 million from $8.6 million in Q1 2025.
- Gross margins expanded to approximately 80% in Q1 2026, up from 62% in Q1 2025.
- Operating loss improved to $4.3 million in Q1 2026 from $4.5 million in Q1 2025.
- Adjusted EBITDA improved by $0.8 million to $(3.6) million from $(4.4) million in Q1 2025.
- Cash used in operations was $70 thousand, a significant improvement from $4.1 million in Q1 2025.
- FDA accepted sNDA for Ameluz® PDT for sBCC, with a PDUFA target date of September 28, 2026.
- Positive Phase 3 results for Ameluz® PDT in mild to moderate actinic keratoses met the primary endpoint.
- Positive Phase 2b results for Ameluz® PDT in moderate to severe acne vulgaris showed 58% lesion reduction.